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CASE REPORT
Invasive trichosporonosis treated
with voriconazole
Vaibhav Garg,a Elizabeth K. Jones, MD,b Ben J. Friedman, MD,b Jason B. Lee, MD,b and Sherry Yang, MDb
State College and Philadelphia, Pennsylvania
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INTRODUCTION
Trichosporon is a genus of yeast-like fungi. It is
perhaps most widely known as the cause of white
piedra, a benign superficial mycosis seen in immu-
nocompetent individuals in tropical and subtropical
regions. However, the incidence of invasive tricho-
sporonosis has increased in immunocompromised
patients, most notably those with hematologic ma-
lignancies. The following case illustrates character-
istic features of trichosporonosis fungemia.
CASE
A 24-year-old black woman with acute myeloid
leukemia (AML) recalcitrant to 2 prior courses of
chemotherapy was admitted for high-dose cytara-
bine. She had neutropenic fever and remained febrile
despite standard empiric antimicrobial coverage with
piperacillin/tazobactam and anidulafungin. Com-
puted tomography scans for dyspnea and worsening
fever revealed paranasal sinus mucosal disease, pul-
monary infiltrates, and axillary lymphadenopathy.
Anidulafungin was switched to amphotericin to cover
potential mucormycosis. A fungal smear endoscopi-
cally obtained from the left maxillary sinus revealed
budding yeast. Blood cultures confirmed growth of
Trichosporon asahii, after which her antifungal
regimen was changed to fluconazole.
Five days after the first positive blood culture, red-
to-violaceous papulo-nodules and pustules devel-
oped on the patient’s face, neck, trunk, and extrem-
ities (Fig 1, A and B). A skin biopsy and tissue culture
were obtained from the forearm. Step sections and a
periodic acid-Schiff stain highlighted a small focus of
suppurative inflammation along with periodic acid-
Schiffepositive spores and pseudohyphae (Fig 2, A).
A tissue culture confirmed T. asahii in the skin. T.
asahiiwas visualized on peripheral blood smear (Fig
2, B) and grew from 8 separate blood cultures
despite treatment with fluconazole. The patient
decompensated and was transferred to the medical
intensive care unit, at which point voriconazole was
initiated. After this change in therapy and slow
recovery of her blood counts, the patient improved
over 1 month with resolution of her fever, dyspnea,
and rash. A repeat bone marrow biopsy confirmed
marrow recovery and complete remission of AML.
DISCUSSION
Over the past decade, the taxonomy of the genus
Trichosporon has been revised on the basis of
molecular data. The formerly named T. beigelii (or
T. cutaneum) now corresponds to 6 different species
that can lead to invasive fungal infections. These
include T. asahii, T. asteroids, T. cutaneum, T. inkin,
T. mucoides, and T. ovoides.1,2 The incidence of
invasive trichosporonosis has risen in large part due
to the increased use of intensive cytotoxic therapy,
allogenic blood stem cell transplantation, and immu-
nosuppressive therapy.1-3 Most cases present in
patients with hematologic malignancy, commonly
AML, during periods of profound neutropenia1,2 In
fact, trichosporonosis is second only to Candida
species as the most frequent cause of fungemia in
patients with hematologic malignancy.1 Most cases
occur as a breakthrough infection, despite standard
Abbreviation used:
AML: acute myeloid leukemia
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prophylactic antifungal regimens.4 Mortality rates are
in excess of 80%.3
Dermatologic findings of invasive trichosporono-
sis might include erythematous papules, bullae,
ulcerations, or necrosis.5 On histopathology, dermal
pseudohyphae and yeast forms can be identified.1,3
Other features include renal failure, pulmonary in-
filtrates, and chronic liver disease.1 Trichosporonosis
must be distinguished from candidiasis, which shares
similar clinical and morphologic features in the
disseminated form.
Optimal therapy for disseminated Trichosporon is
not established. Multidrug resistance has been
reported with amphotericin, echinocandins,
flucytosine, fluconazole, and itraconazole.1-3,6
Clinical and in vitro evidence suggests susceptibility
to newer triazoles including voriconazole, posaco-
nazole, and ravuconazole.2,6 Resolution of tricho-
sporonosis was associated with neutrophil recovery,
mitigation of hyperglycemia, and use of azole-
containing antifungal therapies in a retrospective
study of patients with hematologic malignancies.4
Dermatologists and dermatopathologists should
be aware of the similarities in presentation between
invasive trichosporonosis and Candida and their
differences in treatment susceptibility. Early detec-
tion of trichosporonosis via recognition of clinical,
histologic, and systemic features can aid in rapid
Fig 1. A and B, Clinical presentation of trichosporonosis. Pink-to-red edematous papules and
pustules present on neck and upper chest.
Fig 2. Histopathologic examination of samples from patient with trichosporonosis. A, PAS-
positive spores and pseudohyphae. B, Potassium hydroxide preparation and calcofluor white
fungal stain of peripheral blood smear revealed presence of numerous pseudohyphae. (A, PAS
stain; B, calcofluor white stain; original magnifications: A, 3400; B, 3200.) PAS, Periodic acid-
Schiff.
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treatment and improved outcomes for this rare and
fatal infection. Prognosis remains poor without im-
mune reconstitution.1
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